Pegsunercept
| Clinical data | |
|---|---|
| Routes of administration | subcutaneous injection |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C502H758N154O165S16 |
| Molar mass | 12103.46 g·mol−1 |
  (what is this?) (verify) | |
Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010[update], Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.
Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
